MediaPharma (MP), a biotech company focusing on the discovery and development of monoclonal antibodies, bispecifics and antibody drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer, today announce that they have signed a license and a supply agreement that will allow MP to develop Nerviano’s ‘payload’ (drug-linker) technology on a MP-exclusive target for an ADC designed to meet unmet needs in the field of cancer.
As a result of this agreement, Nerviano will receive undisclosed fees, development linked milestones and royalties for granting MP access to its technology. Nerviano will lead the effort in the manufacture and supply of its payload technology.
Nerviano’s payload technology of new DNA intercalating agents is based on a proprietary thienoindole scaffold, characterized both by potent antitumor activity and by physicochemical properties that are highly compatible with deployment as antibody payloads. Nerviano’s core technologies in the field further include: medicinal chemistry expertise, know-how for establishing proof of concept, GMP manufacturing of payloads as well as efficacy and safety profiling of ADC’s.
Jean-Frédéric Sauniere, M.D., Ph.D., Chief Executive Officer at MediaPharma, commented: “This collaboration with NMS brings to Mediapharma great assets to complement our expertise in immuno-oncology, in particular for the creation of new ADCs against key targets and therefore offering hope for our patients.”
Stefano Iacobelli, M,D. Co-founder and Chief Scientific Officer at MediaPharma, commented: “Antibody-Drug Conjugates (ADCs) are a developing area of cancer drug technology that offers selective targeting of cancer cells. This targeted ADC approach has the potential to optimize the delivery of the cancer drug to the tumor. This means that, in contrast to traditional chemotherapy these novel agents target and attack the cancer cell so that healthy cells are less severely affected. So far, three ADCs have been approved for cancer treatment, but all leading Pharmas are in the process of developing and launching ADCs therapeutics."
Barbara Marenco, President of Nerviano Medical Sciences, commented: “We are very pleased to have signed this licensing deal with MediaPharma. This new agreement marks an additional achievement in our strategic alliances objectives and we are excited about the prospect of expanding the potential of our payload technology platform through new valuable collaborations.”